Human mu opioid receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 22, 2011, Pages 9268-9273

  Ray, Riju ^a   Ruparel, Kosha ^b   Newberg, Andrew ^c   Wileyto, E Paul ^a   Loughead, James W ^b   Divgi, Chaitanya ^d   Blendy, Julie A ^b   Logan, Jean ^e   Zubieta, Jon Kar ^f   Lerman, Caryn ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e BROOKHAVEN NATIONAL LABORATORY   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Genetics; Neuroimaging; Tobacco

Indexed keywords

ALANINE; CARFENTANIL; GLYCINE; MU OPIATE RECEPTOR; NICOTINE;

ALLELE; AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; GENOTYPE; HOMOZYGOTE; HUMAN; IN VIVO STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; THALAMUS; WILD TYPE;

ADULT; BRAIN; BRAIN MAPPING; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NICOTINE; POLYMORPHISM, GENETIC; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, OPIOID, MU; SMOKING; TOBACCO;

NICOTIANA TABACUM;

EID: 79959351336     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1018699108     Document Type: Article

References (55)

1. Lerman C, et al. (2007) Translational research in medication development for nicotine dependence. Nat Rev Drug Discov 6:746-762. (Pubitemid 47338182)
2. Berrendero F, Kieffer BL, Maldonado R (2002) Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice. J Neurosci 22:10935-10940. (Pubitemid 36005169)
3. Trigo JM, Martin-García E, Berrendero F, Robledo P, Maldonado R (2010) The endogenous opioid system: A common substrate in drug addiction. Drug Alcohol Depend 108:183-194.
4. Walters CL, Cleck JN, Kuo YC, Blendy JA (2005) Mu-opioid receptor and CREB activation are required for nicotine reward. Neuron 46:933-943. (Pubitemid 40805353)
5. Xue Y, Domino EF (2008) Tobacco/nicotine and endogenous brain opioids. Prog Neuropsychopharmacol Biol Psychiatry 32:1131-1138.
6. Wewers ME, Dhatt RK, Snively TA, Tejwani GA (1999) The effect of chronic administration of nicotine on antinociception, opioid receptor binding and metenkelphalin levels in rats. Brain Res 822:107-113. (Pubitemid 29222834)
7. Boyadjieva NI, Sarkar DK (1997) The secretory response of hypothalamic beta-endorphin neurons to acute and chronic nicotine treatments and following nicotine withdrawal. Life Sci 61:PL59-PL66.
8. Davenport KE, Houdi AA, Van Loon GR (1990) Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: Evidence for nicotine-induced release of endogenous opioids in brain. Neurosci Lett 113:40-46. (Pubitemid 20175254)
9. Nestler EJ (2005) Is there a common molecular pathway for addiction? Nat Neurosci 8:1445-1449.
10. Gelernter J, Kranzler H, Cubells J (1999) Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: Population studies, and allele frequencies in alcohol- and drug-dependent subjects. Mol Psychiatry 4:476-483. (Pubitemid 29497736)
11. Mague SD, Blendy JA (2010) OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend 108:172-182.
12. Lerman C, et al. (2004) The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 4:184-192. (Pubitemid 38786557)
13. Perkins KA, et al. (2008) Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood. Behav Pharmacol 19:641-649.
14. Ray R, et al. (2006) Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. Psychopharmacology (Berl) 188:355-363. (Pubitemid 44387463)
15. Bond C, et al. (1998) Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: Possible implications for opiate addiction. Proc Natl Acad Sci USA 95:9608-9613. (Pubitemid 28506279)
16. Beyer A, Koch T, Schröder H, Schulz S, Höllt V (2004) Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem 89:553-560. (Pubitemid 38534141)
17. Zhang Y, Wang D, Johnson AD, Papp AC, SadéeW(2005) Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 280:32618-32624.
18. Mague SD, et al. (2009) Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. Proc Natl Acad Sci USA 106:10847-10852.
19. Arvidsson U, et al. (1995) Distribution and targeting of a mu-opioid receptor (MOR1) in brain and spinal cord. J Neurosci 15:3328-3341.
20. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ (1988) Anatomy of CNS opioid receptors. Trends Neurosci 11:308-314.
21. Pfeiffer A, Pasi A, Mehraein P, Herz A (1982) Opiate receptor binding sites in human brain. Brain Res 248:87-96. (Pubitemid 12024462)
22. Koob GF, Volkow ND (2010) Neurocircuitry of addiction. Neuropsychopharmacology 35:217-238.
23. Ichise M, et al. (2003) Linearized reference tissue parametric imaging methods: Application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 23:1096-1112. (Pubitemid 37082435)
24. Zubieta JK, et al. (2003) COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 299:1240-1243.
25. Hardin J, et al. (2009) Nicotine withdrawal sensitivity, linkage to chr6q26, and association of OPRM1 SNPs in the SMOking in FAMilies (SMOFAM) sample. Cancer Epidemiol Biomarkers Prev 18:3399-3406.
26. Drakenberg K, et al. (2006) Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers. Proc Natl Acad Sci USA 103:7883-7888.
27. Chong RY, et al. (2006) The mu-opioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress. Neuropsychopharmacology 31:204-211. (Pubitemid 43250957)
28. Lambe EK, Picciotto MR, Aghajanian GK (2003) Nicotine induces glutamate release from thalamocortical terminals in prefrontal cortex. Neuropsychopharmacology 28:216-225.
29. Wang H, Moriwaki A, Wang JB, Uhl GR, Pickel VM (1997) Ultrastructural immunocytochemical localization of mu opioid receptors in dendritic targets of dopaminergic terminals in the rat caudate-putamen. Neuroscience 81:751-771.
30. Wickens JR, Budd CS, Hyland BI, Arbuthnott GW (2007) Striatal contributions to reward and decision making: Making sense of regional variations in a reiterated processing matrix. Ann N Y Acad Sci 1104:192-212. (Pubitemid 47092742)
31. Deb I, Chakraborty J, Gangopadhyay PK, Choudhury SR, Das S (2010) Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction. J Neurochem 112:486-496.
32. Rainville P (2002) Brain mechanisms of pain affect and pain modulation. Curr Opin Neurobiol 12:195-204.
33. Way BM, Taylor SE, Eisenberger NI (2009) Variation in the mu-opioid receptor gene (OPRM1) is associated with dispositional and neural sensitivity to social rejection. Proc Natl Acad Sci USA 106:15079-15084.
34. Scott DJ, et al. (2007) Smoking modulation of mu-opioid and dopamine D2 receptor-mediated neurotransmission in humans. Neuropsychopharmacology 32:450-457. (Pubitemid 46106951)
35. Munafò MR, Elliot KM, Murphy MF, Walton RT, Johnstone EC (2007) Association of the mu-opioid receptor gene with smoking cessation. Pharmacogenomics J 7:353-361. (Pubitemid 47471313)
36. Smith YR, et al. (2006) Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women. J Neurosci 26:5777-5785. (Pubitemid 44315270)
37. Zubieta JK, Dannals RF, Frost JJ (1999) Gender and age influences on human brain mu-opioid receptor binding measured by PET. Am J Psychiatry 156:842-848. (Pubitemid 29260337)
38. Endres CJ, Bencherif B, Hilton J,Madar I, Frost JJ (2003) Quantification of brain mu-opioid receptors with [11C]carfentanil: Reference-tissue methods. Nucl Med Biol 30:177-186. (Pubitemid 36293719)
39. Heinz A, et al. (2005) Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: A positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry 62:57-64. (Pubitemid 40096071)
40. Bencherif B, et al. (2004) Mu-opioid receptor binding measured by [11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence. Biol Psychiatry 55:255-262. (Pubitemid 38117161)
41. Greenwald MK, et al. (2003) Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 28:2000-2009. (Pubitemid 37412109)
42. Strasser AA, Ashare RL, Kozlowski LT, Pickworth WB (2005) The effect of filter vent blocking and smoking topography on carbon monoxide levels in smokers. Pharmacol Biochem Behav 82:320-329. (Pubitemid 41727943)
43. Brody AL, et al. (2009) Brain nicotinic acetylcholine receptor occupancy: Effect of smoking a denicotinized cigarette. Int J Neuropsychopharmacol 12:305-316.
44. Cappelleri JC, et al. (2007) Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addict Behav 32:912-923. (Pubitemid 46282288)
45. Mills RH, Sohn RK, Micevych PE (2004) Estrogen-induced mu-opioid receptor internalization in the medial preoptic nucleus is mediated via neuropeptide Y-Y1 receptor activation in the arcuate nucleus of female rats. J Neurosci 24:947-955. (Pubitemid 38146605)
46. Karp JS, et al. (2003) Performance of a brain PET camera based on anger-logic gadolinium oxyorthosilicate detectors. J Nucl Med 44:1340-1349. (Pubitemid 39655195)
47. Greenwald M, et al. (2007) Buprenorphine duration of action: Mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiatry 61:101-110. (Pubitemid 44855745)
48. Zubieta JK, et al. (2005) Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J Neurosci 25:7754-7762.
49. Accorsi R, Adam LE, Werner ME, Karp JS (2004) Optimization of a fully 3D single scatter simulation algorithm for 3D PET. Phys Med Biol 49:2577-2598. (Pubitemid 38967946)
50. Smith SM, et al. (2004) Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 23(Suppl 1):S208-S219. (Pubitemid 39421720)
51. Hirvonen J, et al. (2009) Measurement of central mu-opioid receptor binding in vivo with PET and [11C]carfentanil: A test-retest study in healthy subjects. Eur J Nucl Med Mol Imaging 36:275-286.
52. Williams RL (2000) A note on robust variance estimation for cluster-correlated data. Biometrics 56:645-646.
53. Clogg CC, Petkova E, Haritou A (1995) Statistical methods for comparing regression coefficients between models. Am J Sociol 100:1261-1293.
54. Sankoh AJ, Huque MF, Dubey SD (1997) Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat Med 16:2529-2542. (Pubitemid 27490059)
55. Scott DJ, Stohler CS, Koeppe RA, Zubieta JK (2007) Time-course of change in [11C] carfentanil and [11C]raclopride binding potential after a nonpharmacological challenge. Synapse 61:707-714. (Pubitemid 47122742)